

elhi, Jan 30: India cricketer Adil Kailf on haled New Zealand's spirit of cricket during the quarter-final against West Indies in the ongoing U-19 World Cup. He further said, "I think why the Kiwis are the most loved team in recent times, because it begins with the legacy being beautifully carried by the next generation of New Zealand. There is a reason why they are the most loved team of our times. Cricket," Kailf said.

Cricket was again at display in the U-19 World Cup as New Zealand took the injured Kiwis' batsman off the field. New Zealand's bowler, Kirk Peng, took the injured batsman off the field. The incident took place in the 48th over of the Kiwis' innings. It was the final ball to be dismissed. The batsman found it difficult to walk off the field due to cramps. It was decided to carry him off the field.

Rohit Sharma also hailed the Kiwis, saying: "So good to see this kind of Cricket at its best. New Zealand had to defeat West Indies in the quarter-final, a difficult encounter, managed to win by two wickets. In 238, Kiwis won in the last over. In the stage, New Zealand was struggling and reduced to 170 in the end, Joey Barnes (8*) and Kristian Walker (46*) took the lead. Now they will face the winner of the quarter-final clash between South Africa and Sri Lanka.

included. Hannon-Dalby and Rhodes toured Nepal with the MCC in November.

expect as Australian cricketers. Australia lost their quarter-final clash against India by 74 runs, and now they will take on either Pakistan or Afghanistan in the 5th playoff semi-final.

gynecomastia and used prescribed medication which contained a prohibited substance.



Hindustan BIOSCIENCES LTD

Plot No: 31, Sagar Co-Operative Housing Society,
Road No: 2, Banjara Hills, Hyderabad - 500 034 India

Phone No: 040-23555161, 23555181, Fax No: 040-40205171

Website: www.hindustanbiosciences.in, Email: pharma.hindustanbio@gmail.com

CIN: L26942TG1991PLCO13564

STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER /NINE MONTHS ENDED 31st DECEMBER, 2019

(Rs. In Lakhs)

SL No.	Particulars	Quarter ended			Nine Months Ended		Year ended (audited)
		31.12.2019 (Unaudited)	30.09.2019 (Unaudited)	31.12.2018 (Unaudited)	31.12.2019 (Unaudited)	31.12.2019 (Unaudited)	
1	Income from Operations						
	(a) Revenue from operations	38.20	13.85	107.03	105.67	313.29	366.34
	(b) Other income	0	-	-	-	-	0.06
	Total Revenue (1)	38.20	13.85	107.03	105.67	313.29	366.40
2	Expenses						
	(a) cost of material consumed	-	-	-	-	-	-
	(b) Purchases of Stock-in-trade	12.53	6.43	73.95	68.63	289.21	292.13
	(c) Changes in Inventories of finished goods, Stock-in-Trade and Work-in-Progress	12.68	6.39	6.88	2.98	(3.21)	(3.45)
	(d) Employee Benefit Expenses	6.24	6.30	6.18	18.88	16.15	22.41
	(e) Finance Costs	0.18	0.30	0.40	0.63	0.78	1.04
	(f) Selling Expenses	0.21	0.18	0.76	0.45	1.22	1.63
	(g) Depreciation and amortisation Expenses	0.30	0.32	0.26	0.90	0.78	1.07
	(h) Other Expenses	4.64	5.29	11.16	16.17	24.83	30.34
	Total Expenses (2)	36.74	28.18	98.62	106.64	303.83	348.17
3	Profit/(Loss) before Exceptional Items and tax (3=1-2)	1.46	(14.23)	7.51	1.13	9.86	11.23
4	Exceptional Items	-	-	-	-	-	-
5	Profit/(Loss) before tax (3-4)	1.46	(14.23)	7.51	1.13	9.86	11.23
6	Tax Expenses						
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax	-	-	-	-	-	(0.23)
7	Profit/(Loss) for the period from continuing operations (5-6)	1.46	(14.23)	7.51	1.13	9.86	11.23
8	Profit/(Loss) from discontinued operations	-	-	-	-	-	-
9	Tax Expenses of discontinued operations	-	-	-	-	-	-
10	Profit/(Loss) from Discontinued operations after tax (8-9)	-	-	-	-	-	-
11	Profit/(Loss) for the period (7+10)	1.46	(14.23)	7.51	1.13	9.86	11.23
12	Other Comprehensive Income						
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period (11+12)	1.46	(14.23)	7.51	1.13	9.86	11.23
14	(excluding Profit/(Loss) and other comprehensive income for the period)						
15	Paid up Equity Capital (Face value of Rs. 10/- each)	1,025.00	1,025.00	1,025.00	1,025.00	1,025.00	1,025.00
16	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						(808.72)
17	Earnings per equity share for continuing operations						
	(A) Basic	0.01	(0.14)	0.07	0.01	0.09	0.11
	(B) Diluted	0.01	(0.14)	0.07	0.01	0.09	0.11
18	Earnings per equity share for discontinuing operations						
	(A) Basic	-	-	-	-	-	-
	(B) Diluted	-	-	-	-	-	-
19	Earnings per equity share after discontinuing & continuing operations						
	(A) Basic	0.01	(0.14)	0.07	0.01	0.09	0.11
	(B) Diluted	0.01	(0.14)	0.07	0.01	0.09	0.11

Notes:

1 The Unaudited Financial Results were taken on record by the Board of Directors in their meeting held on 29.01.2020

2 Previous Year figures have been regrouped whenever necessary.

For Hindustan Bio Sciences Limited

Sd/-

J. Varun Varma
Director

Place : Hyderabad
Date : 29.01.2020

